Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does Initial Atopic Dermatitis Severity Affect Long-Term Abrocitinib Outcomes? A Post Hoc Analysis of Two Randomized Trials

  • By

  • Andrew E. Pink

  • Zakiya P. Rice

  • Melinda J. Gooderham

  • Fang Wang

  • Andreas Wollenberg

  • Pinaki Biswas

  • Gary Chan

  • Justine Alderfer

  • Melissa Watkins

  • October 8, 2026

Share

  • 1

    This post hoc pooled analysis evaluated short- and long-term abrocitinib outcomes by baseline atopic dermatitis severity in two phase 3 trials.

  • 2

    Baseline severity was classified as moderate or severe using PtGA, combined EASI and IGA scores, or percentage of body surface area involved.

  • 3

    Week 16 efficacy and safety were assessed in JADE COMPARE, in which abrocitinib was given with topical medicated therapy.

  • 4

    Long-term outcomes through week 112 were assessed in JADE EXTEND among adults and adolescents receiving abrocitinib, with or without topical corticosteroids.

  • 5

    The analysis reported rapid, sustained improvements in skin clearance and itch across baseline severity subgroups, regardless of the severity assessment method.

Original Source(s)

Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials

  • by Andrew E. Pink, Zakiya P. Rice, Melinda J. Gooderham, Fang Wang, Andreas Wollenberg, Pinaki Biswas, Gary Chan, Justine Alderfer, Melissa Watkins

  • October 8, 2026

Related Content

Efficacy of Upadacitinib in Treating Atopic Dermatitis in Sensitive Regions: Outcomes from a Multicenter Real-World Study on Hand, Head/Neck, and Genital Involvement

Top 10 Evidence-Based Essentials in Dermatology

A structured framework of guidelines, trials, therapies, and tools used in clinical practice

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models